Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cooke Julie						2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX								eck all applic Directo • Officer	Director Officer (give title		10% Owner Other (specify	
(Last) 12780 El	(F L CAMINC	,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022									below) below) Chief Human Resources Officer				er	
(Street)	EGO C.	A	92130								Line	e) <mark>X</mark> Form f						
(City)	(S	tate)	(Zip)											Persor		c triai	TOTIC TREPOR	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transpare (Month)					action 2A. Deemed Execution Date, if any (Month/Day/Year			Code (Instr. 5)						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code V	Amo	ount	(A) or (D)	Price	Transact	Transaction(s) (Instr. 3 and 4)			,o,
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any C				ransaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and of Securiti Underlying Derivative (Instr. 3 and	es g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expira Date	tion	Title	Amount or Number of Shares					
Stock Option	\$79.02	01/31/2022			A		47,401		(1)	01/31/2	2032	Common Stock	47,401	\$0.00	47,401		D	
Restricted Stock Unit	(2)	01/31/2022			A		6,961		(3)	(3)		Common Stock	6,961	\$0.00	6,961		D	

Explanation of Responses:

- 1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- 2. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- 3. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.

Remarks:

/s/ Darin Lippoldt, Attorney-in-02/02/2022

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.